Search Results

South Korea is looking to become the first country in East Asia to legalize medical cannabis, marking a significant milestone in the global industry and a potential turning point in how the drug is perceived in traditionally conservative societies.

On the eve of Canada’s historic launch of its recreational marijuana program, the global cannabis industry appears poised for explosive growth thanks to the confluence of a host of market developments.

GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares.

The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.

It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.

A move to legalize medical marijuana in South Korea picked up a key backer, increasing its chances of approval by the end of this year.

British tobacco giant Imperial Brands is among a group of investors taking a stake in a UK-based medial cannabis startup, the latest foray by Big Tobacco cannabis.

The U.S. Food and Drug Administration has approved a CBD drug – a landmark decision that will trigger the health agency to seek rescheduling from the DEA.